Download App

Log in to access Online Inquiry
Company Overview More
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
CEO: Stonehouse, Jon P.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

BCRX BioCryst Pharmaceuticals

8.500+0.110+1.31%
Close 05/16 20:00 ET
8.640+0.14+1.65%
Pre Mkt Price 05/17 08:09 ET
High
8.740
Open
8.400
Turnover
38.34M
Low
8.140
Pre Close
8.390
Volume
4.53M
Market Cap
1.58B
P/E(TTM)
Loss
52wk High
19.990
Shares
185.58M
P/E(Static)
Loss
52wk Low
7.610
Float Cap
1.38B
Bid/Ask %
33.33%
Historical High
37.250
Shs Float
162.00M
Volume Ratio
0.80
Historical Low
0.600
Dividend TTM
--
Div Yield TTM
850
P/B
-9.60
Dividend LFY
--
Div Yield LFY
10000.00%
Turnover Ratio
2.80%
Amplitude
7.16%
Avg Price
8.460
Lot Size
1
Float Cap
1.38B
Bid/Ask %
33.33%
Historical High
37.250
Shs Float
162.00M
Volume Ratio
0.80
Historical Low
0.600
Dividend TTM
--
P/B
-9.60
Dividend LFY
--
Turnover Ratio
2.80%
Amplitude
7.16%
Avg Price
8.460
Lot Size
1
Price Forecast

No Data

News

Comment